Healthy Returns: New FDA rules affect copycat GLP-1s, and Apple adds health tools to its latest Watch ○
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
The FDA took a step to crack down on compounded GLP-1s, but it's not exactly a win for Novo Nordisk and Eli Lilly. Meanwhile,